Jin-Cherng Lien1,2, Chi-Li Chung3,4, Tur-Fu Huang5, Tsung-Chia Chang1, Kuan-Chung Chen1, Ging-Yan Gao1, Ming-Jen Hsu6,7, Shiu-Wen Huang6,8. 1. School of Pharmacy, China Medical University, Taichung, Taiwan. 2. Department of Medical Research, Hospital of China Medical University, Taichung, Taiwan. 3. Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan. 4. Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine and School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan. 5. Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan. 6. Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 7. Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. 8. Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND AND PURPOSE: Recent development in drug discovery have shown benzimidazole to be an important pharmacophore,. Benzimidazole derivatives exhibit broad-spectrum pharmacological properties including anti-microbial, anti-diabetic and anti-tumour activity. However, whether benzimidazole derivatives are effective in suppressing angiogenesis and its underlying mechanisms remain incompletely understood. In this study, we aim to characterize the anti-angiogenic mechanisms of a novel 2-aminobenzimidazole-based compound, Jzu 17, in an effort to develop novel angiogenesis inhibitor. EXPERIMENTAL APPROACH: Effects of Jzu 17 on endothelial cell proliferation, migration, invasion, and activation of signalling molecules induced by VEGF-A, were analysed by immunoblotting, MTT, BrdU, migration, and invasion assays. We performed tube formation assay, aorta ring sprouting assay, matrigel plug assay, and a mouse model of metastasis to evaluate ex vivo and in vivo anti-angiogenic effects of Jzu 17. KEY RESULTS: Jzu 17 inhibited VEGF-A-induced cell proliferation, migration, invasion, and endothelial tube formation of HUVECs. Jzu 17 suppressed VEGF-A-induced microvessel sprouting ex vivo and attenuated VEGF-A- or tumour cell-induced neovascularization in vivo. Jzu 17 also reduced B16F10 melanoma lung metastasis. In addition, Jzu 17 inhibited the phosphorylation of VEGFR-2 and its downstream signalling molecules in VEGF-A-stimulated HUVECs. Results from computer modelling further showed that Jzu 17 binds to VEGFR-2 with high affinity. CONCLUSIONS AND IMPLICATIONS: Jzu 17 may inhibit endothelial remodelling and suppress angiogenesis through targeting VEGF-A-VEGFR-2 signalling. These results also suggest Jzu 17 as a potential lead compound and warrant the clinical development of similar agents in the treatment of cancer and angiogenesis-related diseases.
BACKGROUND AND PURPOSE: Recent development in drug discovery have shown benzimidazole to be an important pharmacophore,. Benzimidazole derivatives exhibit broad-spectrum pharmacological properties including anti-microbial, anti-diabetic and anti-tumour activity. However, whether benzimidazole derivatives are effective in suppressing angiogenesis and its underlying mechanisms remain incompletely understood. In this study, we aim to characterize the anti-angiogenic mechanisms of a novel 2-aminobenzimidazole-based compound, Jzu 17, in an effort to develop novel angiogenesis inhibitor. EXPERIMENTAL APPROACH: Effects of Jzu 17 on endothelial cell proliferation, migration, invasion, and activation of signalling molecules induced by VEGF-A, were analysed by immunoblotting, MTT, BrdU, migration, and invasion assays. We performed tube formation assay, aorta ring sprouting assay, matrigel plug assay, and a mouse model of metastasis to evaluate ex vivo and in vivo anti-angiogenic effects of Jzu 17. KEY RESULTS:Jzu 17 inhibited VEGF-A-induced cell proliferation, migration, invasion, and endothelial tube formation of HUVECs. Jzu 17 suppressed VEGF-A-induced microvessel sprouting ex vivo and attenuated VEGF-A- or tumour cell-induced neovascularization in vivo. Jzu 17 also reduced B16F10 melanoma lung metastasis. In addition, Jzu 17 inhibited the phosphorylation of VEGFR-2 and its downstream signalling molecules in VEGF-A-stimulated HUVECs. Results from computer modelling further showed that Jzu 17 binds to VEGFR-2 with high affinity. CONCLUSIONS AND IMPLICATIONS: Jzu 17 may inhibit endothelial remodelling and suppress angiogenesis through targeting VEGF-A-VEGFR-2 signalling. These results also suggest Jzu 17 as a potential lead compound and warrant the clinical development of similar agents in the treatment of cancer and angiogenesis-related diseases.
Authors: J Kankanala; A M Latham; A P Johnson; S Homer-Vanniasinkam; C W G Fishwick; S Ponnambalam Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739
Authors: Maurice S Brozzo; Sasa Bjelić; Kaisa Kisko; Thomas Schleier; Veli-Matti Leppänen; Kari Alitalo; Fritz K Winkler; Kurt Ballmer-Hofer Journal: Blood Date: 2011-12-29 Impact factor: 22.113
Authors: Guido Bold; Christian Schnell; Pascal Furet; Paul McSheehy; Josef Brüggen; Jürgen Mestan; Paul W Manley; Peter Drückes; Marion Burglin; Ursula Dürler; Jacqueline Loretan; Robert Reuter; Markus Wartmann; Andreas Theuer; Beatrice Bauer-Probst; Georg Martiny-Baron; Peter Allegrini; Arnaud Goepfert; Jeanette Wood; Amanda Littlewood-Evans Journal: J Med Chem Date: 2015-12-21 Impact factor: 7.446
Authors: V Lakshma Nayak; Narayana Nagesh; A Ravikumar; Chandrakant Bagul; M V P S Vishnuvardhan; Vunnam Srinivasulu; Ahmed Kamal Journal: Apoptosis Date: 2017-01 Impact factor: 4.677
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971